| I N TR ODU C TI ON
Osteochondromatosis a rare skeletal developmental disorder characterized by the appearance of cartilage capped boney outgrowths (exostoses) that continue to develop and grow until skeletal maturity. 1, 2 Exostoses arise from the periosteum of bones that undergo endochondral ossification, frequently but not exclusively near physes. Common sites include the long bones as well as the vertebrae and ribs. Solitary lesions are known as osteochondromas whereas multiple lesions are referred to as osteochondromatosis, or multiple cartilaginous exostoses. Clinical signs may occur as a result of compression of adjacent tissue, for example, pain caused by nerve compression, or paralysis associated with spinal cord compression. In <5% of cases, the benign lesion can undergo malignant transformation. [1] [2] [3] The condition has been reported in people, horses, 4 dogs, 5 and cats, although the condition in cats appears to differ from that in other species, occurring after skeletal maturity. 6 It is inherited as an autosomal dominant trait in people, with >90% of cases being associated with a loss of function mutation in exostosin 1 or 2 (EXT1 or EXT2). 7 Both of these genes encode glycosyltransferases important in the generation heparan sulfate. 8 Although most reports in dogs describe solitary cases, the occurrence of osteochondromatosis in littermates and successive generations of dogs supports a hereditary etiology in this species, but an associated genetic variant has not yet been described. 9, 10 The purpose of our report is to describe the results of an investigation into the genetic cause of osteochondromatosis in a litter of 
| DNA isolation
Approximately 2-3 mL of ethylene diamino tetra-acetic acid (EDTA)-anticoagulated blood was collected from each animal and shipped to the Veterinary Genetics Laboratory at North Carolina State University.
The DNA was extracted using the standard protocol of the DNeasy Blood and Tissue Kit (Qiagen). Quality and concentration of DNA were evaluated using both a spectrophotometer (NanoDrop 1000) and a fluorometer (Qubit 2.0).
| Whole genome sequencing
Approximately 3 lg of DNA from the proband was submitted for Illu- and 42 dogs of 18 additional breeds. Sequence data from all of these dogs were processed using the same bioinformatics pipeline described above. None of the animals in this database were known to have osteochondromatosis or any other similar bone or cartilage disorder. Variants that passed our filtering step were annotated using SnpEff 4.3. 
| Parentage testing
Parentage testing was performed on all offspring and both parents using a commercially available microsatellite-based marker test performed at the University of California Davis Veterinary Genetics Laboratory (https://www.vgl.ucdavis.edu/services/CatandDogDNATyping. php).
| Amplicon-based deep sequencing
Amplicon-based deep sequencing (ADS) was performed on both parents and all offspring to test for genetic mosaicism that could have given rise to a heritable or somatic mutation in EXT2. This technique provides extremely high coverage (>31000) of a particular amplicon so that low-copy-number heterozygotes, which could indicate genetic mosaicism and would ordinarily not be detectable by Sanger sequencing, can be identified. 19 Standard Illumina Nextera sequencing primers were appended to the 5 0 end of the EXT2 primers described above, and PCR was carried out for each dog to generate a 337 bp amplicon with 5 0 and 3 0 tails suitable for barcoding. The PCR amplicons were submitted for Illumina i5 and i7 barcoding, multiplexing, library preparation, and sequencing at UMGC.
All 11 amplicons were pooled in equimolar amounts and sequenced on an Illumina MiSeq Desktop sequencer. Reactions were designed as 2 3 300 bp paired-end reads using Illumina v3 chemistry.
De-multiplexed sequencing reads were processed using the same bioinformatics pipeline as described above, but VQSR was not performed given the small target region. (Figure 1 ).
An MRI diagnosis of osteochondromatosis was made. 20 Based on the findings, the owner elected euthanasia, a necropsy was performed, and the diagnosis of osteochondromatosis was confirmed.
The proband came from a litter of 9 puppies, 4 females and 5 males. A female developed signs of paraparesis at the same time as the proband, with signs also localized to T3-L3 spinal cord segments, and the puppy was euthanized. Necropsy confirmed spinal cord compression secondary to a lesion from the dorsal lamina of T9 as well as a None of these offspring had developed osteochondromatosis to the breeder's knowledge. None of these variants were located in any gene known to be associated with osteochondromatosis in humans.
| Whole genome sequencing

| Sanger sequencing
Sequencing of the proband confirmed a heterozygous variant at chr18:45101754. This same heterozygous variant was noted in the 2 other affected littermates, but not in any of the unaffected littermates, the parents, the grandparents from which DNA was available, or any of the other healthy unrelated American Staffordshire Terriers (Figure 4 ).
These findings suggested a possible de novo mutation in the affected offspring that was unique to this litter. 
| Parentage testing
Parentage was confirmed for all offspring (>99% confidence for each test), indicating that no mismating occurred that could have introduced the identified EXT2 mutation into the affected offspring.
| Amplicon-based deep sequencing
Depth of coverage from ADS across all dogs sequenced ranged from 8800 to 901,9403. For both parents and all unaffected offspring, >99.8% of the reads showed a C (reference) allele at the EXT2 exon 5 mutation site. For the affected offspring, the reads were equally balanced between C and A alleles, ranging from 48.8% to 53.7% of reads for the C allele. One study of osteochondromatosis mutations in humans suggested that somatic mutations or genetic mosaicism may be responsible for osteochondromatosis in the small number of cases for which a germline variant in EXT1 or EXT2 cannot be identified. 27 Because
Sanger sequencing of both parents failed to identify the EXT2 mutation we identified in the 3 affected offspring, we considered this possibility in the affected dogs presented here. However, ADS definitively ruled out genetic mosaicism or any low-level somatic mutation, leading us to conclude that the mutation arose de novo across the litter. We unfortunately were unable to obtain gonadal tissue from either the sire or the dam of this litter to confirm this possibility, however de novo mutations are a widely recognized source of genetic mutations responsible for an array of congenital disorders, 19 including osteochondromatosis in humans. 21, 26 The exostosin family of genes encodes glycosyltransferases that are responsible for the synthesis and assembly of heparan sulfate chains on proteoglycans. [28] [29] [30] Both heparan sulfate and proteoglycans are critically important for normal bone and cartilage development. 31, 32 Because both EXT1 and EXT2 are required for heparan sulfate synthesis, heterozygous mutations in either gene results in systemic deficiency of these molecules in approximately 50% of patients with osteochondromatosis. 33 The exact mechanism by which mutations in EXT1 and EXT2 cause osteochondromatosis is unknown, however 2 theories have been advanced: haploinsufficiency and loss-ofheterozygosity (LOH). 7 The first model suggests that the lower gene dosage associated with a heterozygous mutation causes insufficient amounts of heparan sulfate, and results in an environment in which osteochondromas can proliferate. 7 The LOH model suggests that EXT1
and EXT2 function as tumor suppressor genes, and that loss of function of 1 copy of these genes is followed by a second mutation during a somatic mutation event, which inactivates the tumor suppressor gene and results in the formation of osteochondromas. 2, 34 Although fully elucidating the specific mechanism by which the EXT2 mutation identified here caused osteochondromatosis in this litter of dogs is beyond the scope of our study, mechanistic studies in humans related to the role that the exostosin genes play in causing osteochondromatosis lay the groundwork for future studies in dogs aimed at understanding the underlying pathophysiology of this disease.
Because the mutation identified here arose de novo in this particular litter, it is unlikely that the same mutation would be present in other dogs with osteochondromatosis. Therefore, a genetic test based upon this specific mutation would be unlikely to provide any benefit to diagnosis in other dogs. However, given the genetic epidemiology in humans, which has documented >600 known mutations in EXT1 and EXT2 associated with the disease, future cases of osteochondromatosis in dogs could be confirmed by sequencing both genes in their entirety in affected animals. This type of sequencing-based test could be helpful to breeders, especially in identifying cases that appear to be heritable across generations rather than de novo events.
